AIM
MACK

Advantage Investment Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Advantage Investment Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-95
Closed -$6K – 917
2015
Q3 		$6K Hold
95
– – ﹤0.01% 642
2015
Q2 		$9K Hold
95
– – ﹤0.01% 623
2015
Q1 		$9K Sell
95
-127
-57% -$10.8K 0.01% 616
2014
Q4 		$20K Buy
+222
New +$16.2K 0.01% 427

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

Advantage Investment Management's MACK Position: Q4 2015 in Review

Advantage Investment Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2015, closing a stake of 95 shares — an estimated $6K sold.

Advantage Investment Management first reported a position in MACK in Q4 2014 and held it in 4 quarters. The position peaked at $20K in Q4 2014. 139 funds tracked by Wall St. Rank hold MACK as of Q4 2015.

  • Advantage Investment Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • Advantage Investment Management sold 95 Merrimack Pharmaceuticals, Inc. shares in Q4 2015, an estimated $6K.
  • Advantage Investment Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2014 and held it in 4 quarters.
  • Advantage Investment Management's Merrimack Pharmaceuticals, Inc. position peaked at $20K in Q4 2014.
  • 139 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2015.

Based on Advantage Investment Management's 13F filing for Q4 2015, filed 27 Mar 2017.